Medico-economic assessment of haemophilia A at the dawn of the new millennium;L'évaluation médico-économique de l'hémophilie à l'aube du troisième millénaire

Hematologie

Volumn 7, Issue 6, 2001, Pages 445-452

  Jasso Mosqueda, Juan Guillermo ^a   Omnes, Louis François ^a   Chicoye, Annie ^a   Durand Zaleski, Isabelle ^a  

^a Annie Chicoye Economics   (France)

Author keywords

Cost; Haemophilia A; Medico economic assessment

Indexed keywords

BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HEMOPHILIA; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY;

EID: 0035724819     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Recommondations de bonnes pratiques des méthodes d'évaluation économique des stratégies théropeutiques
2. Prophylactic use of factor VIII: An economic evaluation
3. Treatment of patients with inhibitors: Cost issues
4. Prophylactic therapy for hemophilia in a developing country, Turkey
5. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease
6. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis
7. The econamics of replacement therapy
8. Resource utilisation in haemophiliacs treated in Europe: Results from the European Study on Socioeconamic Aspects of Haemophilia Care
9. The incidence of cator VIII inhibitors in patients with severe hemophilia A
10. Determining inhibitor-development risk in previously untreated patients with hemophilia A
11. The economics of immune tolerance and treatment of hemophiliacs with inhibitors
12. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates
13. National haemophilia treatment protocols: Canada
14. Recommendatians for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Director's Organisation Working Party
15. Haemophilia care within the United Kingdom
16. Guidelines on treatment of hemophilia in Sweden
17. Prophylaxis for hemophilia: State of the art or state of confusion?
18. The economics of factor VII inhibitor treatement